Because of the high levels of estrogen deprivation caused by aromatase inhibitors, the effect of such inhibition on lipid profiles and thus cardiovascular disease [24-26] has been a concern, especially considering the protective effects that tamoxifen exerts on lipid profiles [27,28]. This evidence concerns the gene CYP19A1 and cardiovascular disorder.